INCATE supports innovators
to fight drug-resistant bacterial infections
Our Mission
Supporting innovators to fight drug-resistant infections
INCATE brings together translational and basic research, industry, experienced entrepreneurs and investors from across Europe to accelerate your innovation. We do this by providing advice, community and funding. Our focus is on the development of new therapies, and interventions that help reduce the prevalence and impact of Antimicrobial Resistance (AMR).
Whats up?
Latest News
Every year, selecting the finalists for the Startup Pitch Event becomes more challenging, and 2026 was no exception. The level of creativity, ambition, and innovation we saw this year was truly impressive. A huge thank-you [...]
January 21, 2026 – The Japan Pharmaceutical Manufacturers Association (JPMA) has joined forces with INCATE [...]
January 13, 2026 — INCATE (INCubator for Antibacterial Therapies in Europe), the antimicrobial incubator supporting [...]
Just before turning the page to 2026, it’s worth pausing to reflect on both the [...]
The INCATE Management team is happy to announce the release of INCATE’s first report, covering [...]
What we do
Supporting your venture
Advice
Advice from partners, including Industry, to enable; early alignment with medical needs and market demand, the development of a quality translational path and a plan to build a company.
Community
Access to a community of engaged individuals across industry, academia, entrepreneurs, policymakers, investors, public health and healthcare providers to share ideas and fight drug-resistant bacterial infections together.
Funding
Up to €250,000 in non-dilutive funding will be provided to selected projects to help answer critical questions needed to develop business and translational plans to convince investors at the next funding stage.
